- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00973479
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
November 29, 2013 updated by: Centocor, Inc.
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to evaluate clinical effectiveness and safety of golimumab with methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) when compared to MTX alone.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a randomized (study medication is assigned by chance), double-blind (neither physician nor participants knows the treatment that the participant receives), placebo-controlled (an inactive substance is compared with a medication to test whether the medication has a real effect in a clinical study), multicenter, 2-arm (2 groups) study of golimumab in participants with active RA despite concurrent MTX therapy.
Approximately 564 participants will be randomly allocated to 1 of 2 treatment groups in a 2:1 ratio ie, Group 1(approximately 376 participants will receive golimumab + MTX) and Group 2 (approximately 188 participants will receive MTX + placebo).
Total duration of study for each participant is 112 weeks.
Safety will be evaluated by assessment of adverse events, tuberculosis testing and blood testing.
Study Type
Interventional
Enrollment (Actual)
592
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina
-
Buenos Aires N/A, Argentina
-
Cordoba, Argentina
-
Rosario, Argentina
-
San Juan, Argentina
-
San Miguel De Tucuman, Argentina
-
Santa Fe, Argentina
-
-
-
-
-
Cairns, Australia
-
Maroochydore, Australia
-
Melbourne, Australia
-
Woodville, Australia
-
Woolloongabba, Australia
-
-
-
-
-
Antioquia, Colombia
-
Barranquilla, Colombia
-
Bogota, Colombia
-
Cali Valley Del Cauca, Colombia
-
Medellin, Colombia
-
-
-
-
-
Budapest, Hungary
-
Debrecen, Hungary
-
Eger, Hungary
-
Gyor, Hungary
-
Gyula, Hungary
-
Szombathely, Hungary
-
Veszprem, Hungary
-
-
-
-
-
Anyang, Korea, Republic of
-
Dae-Gu, Korea, Republic of
-
Daejeon, Korea, Republic of
-
Incheon, Korea, Republic of
-
Pusan, Korea, Republic of
-
Seoul, Korea, Republic of
-
-
-
-
-
Alytus, Lithuania
-
Kaunas, Lithuania
-
Klaipeda, Lithuania
-
Siauliai, Lithuania
-
Vilnius, Lithuania
-
-
-
-
-
Georgetown, Malaysia
-
Ipoh, Malaysia
-
Johor Bahru, Malaysia
-
Kota Kinabalu, Malaysia
-
Kuantan, Malaysia
-
Kuching, Malaysia
-
Precinct 7, Malaysia
-
Selangor Darul Ehasan, Malaysia
-
Seremban, Malaysia
-
-
-
-
-
Guadalajara, Mexico
-
Leon, Mexico
-
Mex, Mexico
-
Mexico, Mexico
-
Monterrey, Mexico
-
-
-
-
-
Auckland, New Zealand
-
Takapuna Auckland, New Zealand
-
Timaru, New Zealand
-
-
-
-
-
Bialystok, Poland
-
Bydgoszcz, Poland
-
Dzialdowo, Poland
-
Elblag, Poland
-
Katowice, Poland
-
Lublin, Poland
-
Poznan, Poland
-
Sopot, Poland
-
Szczecin, Poland
-
Warszawa, Poland
-
Wloszczowa, Poland
-
Wrocław, Poland
-
-
-
-
-
Chelyabinsk, Russian Federation
-
Ekaterinburg, Russian Federation
-
Krasnoyarsk, Russian Federation
-
Moscow, Russian Federation
-
Moscow N/A, Russian Federation
-
Petrozavodsk, Russian Federation
-
Saint Petersburg, Russian Federation
-
Saratov, Russian Federation
-
St.Petersburg, Russian Federation
-
-
-
-
-
Donetsk, Ukraine
-
Ivano-Frankovsk, Ukraine
-
Kharkiv, Ukraine
-
Kyiv, Ukraine
-
Odessa, Ukraine
-
Simferopol, Ukraine
-
Ternopil, Ukraine
-
Vinnitsa, Ukraine
-
Zaporizhzhya, Ukraine
-
-
-
-
Florida
-
Daytona Beach, Florida, United States
-
Miami, Florida, United States
-
Palm Harbor, Florida, United States
-
-
Illinois
-
Moline, Illinois, United States
-
-
Maryland
-
Wheaton, Maryland, United States
-
-
Massachusetts
-
Worcester, Massachusetts, United States
-
-
Nebraska
-
Lincoln, Nebraska, United States
-
-
Ohio
-
Cincinnati, Ohio, United States
-
-
Texas
-
Lubbock, Texas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of rheumatoid arthritis (RA) for at least 3 months prior to screening
- Have been treated with and tolerated methotrexate (MTX) at a dose of at least 15 mg/week for at least 3 months prior to screening, and have been on a stable MTX dose of 15 mg/week to 25 mg/week for at least 4 weeks prior to screening
- Have an active RA, as defined by disease activity with at least 6 swollen and 6 tender joints, at the time of screening and at baseline
- C-Reactive Protein greater than or equal to 1.0 mg/dL at screening
- No history of latent or active tuberculosis prior to screening
Exclusion Criteria:
- Other inflammatory diseases, including but not limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, or lyme disease
- Treated with disease modifying agents (other than methotrexate)/systemic immunosuppressives (eg, D-penicillamine, hydroxychloroquine, chloroquine, oral or parenteral gold, sulfasalazine, leflunomide, azathioprine, cyclosporine, mycophenolate mofetil) during the 4 weeks prior to first administration of study agent
- Received intra-articular (in the joint), intramuscular (in the muscle), or intravenous corticosteroids, including adrenocorticotropic hormone, during the 4 weeks prior to first administration of study agent
- Known allergy to human immunoglobulin proteins or other components of golimumab
- Received any commercial or investigational anti-tumor necrosis factor alpha therapy such as but not exclusively infliximab, golimumab, adalimumab or etanercept
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group I: Placebo + Methotrexate (MTX)
Participants will receive placebo at Weeks 0, 4, 12, and 16.
Participants will cross over to golimumab at Week 24, and receive administrations at Weeks 24, 28, and every 8 weeks thereafter.
They will be maintained on their stable dose of commercial methotrexate throughout the study.
Participants will be eligible for early escape (receive golimumab) at Week 16 if they demonstrate a less than 10 percent improvement in both tender and swollen joint count.
These participants will receive golimumab at Weeks 16, 20, and every 8 weeks thereafter.
|
Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes.
Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100).
Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
|
Placebo Comparator: Group II: Golimumab + Methotrexate (MTX)
Participants will receive golimumab at Weeks 0, 4, and every 8 weeks thereafter.
They will be maintained on their stable dose of commercial methotrexate throughout the study.
Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.
|
Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes.
Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100).
Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14
Time Frame: Week 14
|
An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen (66 joints) and tender (68 joints) joint counts; 2. greater than or equal to 20 percentage improvement in at least 3 of the following 5 assessments: a. Participant's assessment of pain by Visual Analog Scale (VAS), (0 [no pain] to 10 [worst pain]) b.
Participant's global assessment of disease activity by VAS c. Physician's global assessment of disease activity by VAS d.
Participant's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C-reactive protein.
|
Week 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Participants With Moderate or Good Response in Disease Activity Index Score 28 (DAS28) Using C-reactive Protein (CRP) at Week 14
Time Frame: Week 14
|
DAS28 using CRP is an index to measure the disease activity in participants with rheumatoid arthritis combining tender joints (28 joints), swollen joints (28 joints), CRP, and participant's global assessment of disease activity.
The DAS28 score ranges from 0 (best) to 10 (worst).
DAS28 score above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity.
Higher scores indicate worsening.
A decrease in DAS28 score >1.2 is being referred to as a "good response" and a decrease of 0.6-1.2 as a "moderate response".
|
Week 14
|
Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14
Time Frame: Week 14
|
The HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living).
Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area).
HAQscore on a scale ranges from 0 (no disability) to 3 (completely disabled).
Higher scores indicate worsening.
|
Week 14
|
Proportion of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24
Time Frame: Week 24
|
An ACR 50 response is defined as a greater than or equal to 50 percent improvement from baseline in: 1. Swollen (66 joints) and tender (68 joints) joint counts; 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm) b.
Participant's global assessment of disease activity by VAS (0-10 cm) c.
Physician's global assessment of disease activity by VAS (0-10 cm) d.
Participant's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.
|
Week 24
|
Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24.
Time Frame: Week 24
|
Total vdH-S score is sum of joint erosion score and joint-space narrowing (JSN) score.
Joint erosion score summarizes erosion severity in 32 joints of hands and 12 joints of feet.
Each joint scored from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone).
Maximal erosion score is 280.
JSN score summarizes severity of JSN in 30 joints of hands and 12 joints of feet.
Assessment of JSN, including subluxation, is scored from 0 (normal) to 4 (bony ankylosis or complete luxation).
Maximal JSN score is 168.
Thus, the worst possible vdH-S score is 448.
|
Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Husni ME, Deodhar A, Schwartzman S, Chakravarty SD, Hsia EC, Leu JH, Zhou Y, Lo KH, Kavanaugh A. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis Res Ther. 2022 Mar 21;24(1):73. doi: 10.1186/s13075-022-02753-6.
- Lee JB, Broadwell A, Fan Y, Hu C, Adedokun OJ, Chakravarty SD, Zhou H, Xu Z, Leu JH. Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis. Clin Ther. 2022 Mar;44(3):457-464.e2. doi: 10.1016/j.clinthera.2022.01.015. Epub 2022 Feb 17.
- Tesser J, Kafka S, DeHoratius RJ, Xu S, Hsia EC, Turkiewicz A. Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those >/= 65 years of age. Arthritis Res Ther. 2019 Aug 20;21(1):190. doi: 10.1186/s13075-019-1968-x.
- Standish KA, Huang CC, Curran ME, Schork NJ. Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies. Arthritis Res Ther. 2017 May 12;19(1):90. doi: 10.1186/s13075-017-1299-8.
- Bingham CO 3rd, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME; GO-FURTHER Investigators. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1627-36. doi: 10.1002/acr.22556.
- Bingham CO 3rd, Weinblatt M, Han C, Gathany TA, Kim L, Lo KH, Baker D, Mendelsohn A, Westhovens R. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. J Rheumatol. 2014 Jun;41(6):1067-76. doi: 10.3899/jrheum.130864. Epub 2014 May 1.
- Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, Noonan L, Lu J, Xu Z, Leu J, Baker D, Bingham CO; GO-FURTHER investigators. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Ann Rheum Dis. 2014 Dec;73(12):2152-9. doi: 10.1136/annrheumdis-2013-203742. Epub 2013 Sep 3.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
February 1, 2013
Study Registration Dates
First Submitted
September 4, 2009
First Submitted That Met QC Criteria
September 4, 2009
First Posted (Estimate)
September 9, 2009
Study Record Updates
Last Update Posted (Estimate)
December 25, 2013
Last Update Submitted That Met QC Criteria
November 29, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Tumor Necrosis Factor Inhibitors
- Methotrexate
- Golimumab
Other Study ID Numbers
- CR015784
- CNTO148ART3001 (Other Identifier: Centocor, Inc)
- 2008-006064-11 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Rheumatoid
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
David Grant U.S. Air Force Medical CenterCompleted
-
TcLand Expression S.A.European CommissionTerminatedRheumatoId ArthritisFrance, Netherlands, Turkey, Czechia, Israel
Clinical Trials on Golimumab
-
Janssen Research & Development, LLCMerck Sharp & Dohme LLCCompletedColitis, UlcerativeUnited States, France, Poland, Ukraine, Germany, Belgium, Israel, Bulgaria, India, Romania, Serbia, South Africa, Japan, Canada, Australia, Netherlands, New Zealand, Russian Federation, Czech Republic, Hungary, Austria, Denmark, Lit... and more
-
Janssen Research & Development, LLCMerck Sharp & Dohme LLCCompletedColitis, UlcerativeUnited States, Canada, France, Poland, Ukraine, Germany, Israel, Bulgaria, India, Romania, Serbia, South Africa, Japan, Australia, Netherlands, Sweden, Belgium, New Zealand, Russian Federation, Czech Republic, Hungary, Austria, Denmark and more
-
Centocor, Inc.Schering-PloughCompletedArthritis, PsoriaticUnited States, Poland, United Kingdom, Spain, Canada, Belgium
-
Centocor, Inc.Schering-PloughCompletedSpondylitis, AnkylosingUnited States, Germany, Finland, Taiwan, Korea, Republic of, Canada, Belgium, Netherlands, France
-
Hospital de ManisesMerck Sharp & Dohme LLC; Hospital Arnau de Vilanova; Hospital Universitario La... and other collaboratorsUnknown
-
Janssen Research & Development, LLCMerck Sharp & Dohme LLCTerminatedColitis, UlcerativeUnited States, Poland, Germany, France, India, Romania, Serbia, Ukraine, Israel, Canada, Netherlands, Sweden, New Zealand, Russian Federation, Australia, Belgium, Hungary, Bulgaria, Slovakia, Latvia, Lithuania, Austria
-
Centocor, Inc.Schering-PloughCompletedArthritis, RheumatoidUnited States, Australia, United Kingdom, Germany, Spain, Canada, Finland, Austria, New Zealand, Netherlands
-
Alvotech Swiss AGActive, not recruitingRheumatoid ArthritisBulgaria
-
Centocor, Inc.CompletedHealthy VolunteersUnited States
-
Merck Sharp & Dohme LLCCompleted